Sanofi and Regeneron’s once close relationship has been become a little more distant over the last couple of years, and the process continued this week after Sanofi said it wil
A scientist leading the development of Oxford University’s coronavirus vaccine says the just-started phase 2/3 trial only has a 50:50 chance of success, because the virus is di
There are reasons to be optimistic over the cutting-edge mRNA vaccines being developed to end the COVID-19 pandemic, according to an expert in the field.
New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit the mark in a pivotal trial.
The disruption caused by the coronavirus crisis hasn’t dampened the enthusiasm of European venture capitalists to make funding available to healthcare companies, says a ne